Prasham Dave
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Prasham Dave has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Alice Moroni
Structural Heart Program, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
4 shared publications Abdulaziz Al-Shaibi
3 shared publications- Dar Dowlatshahi
Department of Medicine (Neurology), University of Ottawa and Ottawa Hospital Research Institute, ON, Canada (D.D.).
3 shared publications - Kitae Kim
Structural Heart Program, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
3 shared publications - Neil P. Fam
Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
3 shared publications Sami Alnasser
3 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Elsevier in Structural Heart
- Vol. 10 (11)
Rim Augmentation to Facilitate Gore Distal Disc Cupping for a Large Atrial Septal Defect Closure
- 12 August 2026
- Published by Elsevier in Structural Heart
- Vol. 10 (11)
Open AccessRim Augmentation to Facilitate Gore Distal Disc Cupping for a Large Atrial Septal Defect Closure
- Open Access
- 14 July 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (34) , 109310
Leaflet-to-Ring Edge-to-Edge Repair With Paravalvular Leak Closure for Dehisced Surgical Mitral Annuloplasty
- 14 July 2026
- Published by Elsevier in JACC: Case Reports
- Vol. 31 (34) , 109310
Open AccessLeaflet-to-Ring Edge-to-Edge Repair With Paravalvular Leak Closure for Dehisced Surgical Mitral Annuloplasty
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1681-1682
UNICORN for Native Transcatheter Aortic Valve Replacement in a Bicuspid Aortic Valve
- 22 June 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (12) , 1681-1682
UNICORN for Native Transcatheter Aortic Valve Replacement in a Bicuspid Aortic Valve
- 11 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2043-2058
Pulmonary Artery Pulsatility Index and Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Replacement
- 11 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (15) , 2043-2058
Pulmonary Artery Pulsatility Index and Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Replacement
- Open Access
- 6 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2414-2426
The Utilization of Superficial Femoral Artery Access for Transcatheter Aortic Valve Replacement and Peripheral Vascular Interventions: A Systematic Review and Meta‐Analysis
The superficial femoral artery (SFA) is a vascular access alternative for various cardiovascular interventions, especially when the common femoral artery CFA is deep, calcified or in high bifurcation. SFA use, however, was associated with pseudoaneurysms in older literature, and its utilization for large‐bore access is not well established. We conducted a systematic review, including randomized and observational studies that reported on SFA vascular access for peripheral arterial disease (PAD), and transcatheter aortic valve replacement (TAVR) from inception until October 2024. The pooled weighted averages of SFA‐related vascular complications were calculated. In addition, the random‐effects model was used to estimate the pooled odds ratio (OR) comparison between SFA and CFA across the included studies. The primary endpoint was vascular complications. The search yielded 1269 articles; 27 (22 in PAD, 5 in TAVR) met our pre‐specified inclusion criteria. Among the PAD studies, 19 were observational, and three were randomized clinical trials. The weighted averages for vascular complications and pseudoaneurysms were 9.8% (95% CI 6.1%−15.6%) and 2.7% (95% CI 1.5%−4.9%), respectively. The meta‐analysis included six studies (five observational and one randomized) that compared outcomes of SFA (838 patients) and CFA (604 patients) and showed no significant difference in the rates of vascular complications (5.4% in the SFA group and 6.4% in the CFA group, OR 0.71, 95% CI [0.40−1.27]; p = 0.25%). Among the TAVR studies, SFA was used as the primary access in 18 patients, with no significant bleeding, vascular complications, or unplanned interventions. In this analysis, SFA access was associated with good safety in selected patients undergoing peripheral arterial procedures (low to intermediate risk of bias). It was also feasible as the primary access route for TAVR in a very small, highly selected group with unfavorable CFA anatomy (high risk of bias) and therefore is hypothesis‐generating, requiring validation in larger studies.
- 6 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2414-2426
Open AccessThe Utilization of Superficial Femoral Artery Access for Transcatheter Aortic Valve Replacement and Peripheral Vascular Interventions: A Systematic Review and Meta‐Analysis
The superficial femoral artery (SFA) is a vascular access alternative for various cardiovascular interventions, especially when the common femoral artery CFA is deep, calcified or in high bifurcation. SFA use, however, was associated with pseudoaneurysms in older literature, and its utilization for large‐bore access is not well established. We conducted a systematic review, including randomized and observational studies that reported on SFA vascular access for peripheral arterial disease (PAD), and transcatheter aortic valve replacement (TAVR) from inception until October 2024. The pooled weighted averages of SFA‐related vascular complications were calculated. In addition, the random‐effects model was used to estimate the pooled odds ratio (OR) comparison between SFA and CFA across the included studies. The primary endpoint was vascular complications. The search yielded 1269 articles; 27 (22 in PAD, 5 in TAVR) met our pre‐specified inclusion criteria. Among the PAD studies, 19 were observational, and three were randomized clinical trials. The weighted averages for vascular complications and pseudoaneurysms were 9.8% (95% CI 6.1%−15.6%) and 2.7% (95% CI 1.5%−4.9%), respectively. The meta‐analysis included six studies (five observational and one randomized) that compared outcomes of SFA (838 patients) and CFA (604 patients) and showed no significant difference in the rates of vascular complications (5.4% in the SFA group and 6.4% in the CFA group, OR 0.71, 95% CI [0.40−1.27]; p = 0.25%). Among the TAVR studies, SFA was used as the primary access in 18 patients, with no significant bleeding, vascular complications, or unplanned interventions. In this analysis, SFA access was associated with good safety in selected patients undergoing peripheral arterial procedures (low to intermediate risk of bias). It was also feasible as the primary access route for TAVR in a very small, highly selected group with unfavorable CFA anatomy (high risk of bias) and therefore is hypothesis‐generating, requiring validation in larger studies.
- Open Access
- 11 November 2022
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 8 (3) , 194-196
Aetiology of extracranial carotid free-floating thrombus in a prospective multicentre cohort
Background Carotid free-floating thrombi (FFT) in patients with acute transient ischaemic attack (TIA)/stroke have a high risk of early recurrent stroke. Management depends on aetiology, which can include local plaque rupture, dissection, coagulopathy, malignancy and cardioembolism. Our objectives were to classify the underlying aetiology of FFT and to estimate the proportion of patients with underlying stenosis requiring revascularisation. Methods We prospectively enrolled consecutive patients presenting to three comprehensive stroke centres with acute TIA/stroke and ipsilateral internal carotid artery FFT. The aetiology of FFT was classified as: carotid atherosclerotic disease, carotid dissection, cardioembolism, both carotid atherosclerosis and cardioembolism, or embolic stroke of uncertain source (ESUS). Patients with carotid atherosclerosis were further subclassified as having ≥50% or Results We enrolled 83 patients with confirmed FFT. Aetiological assessments revealed 66/83 (79.5%) had carotid atherosclerotic plaque, 4/83 (4.8%) had a carotid dissection, 10/83 (12%) had both atrial fibrillation and carotid atherosclerotic plaque and 3/83 (3.6%) were classified as ESUS. Of the 76 patients with atherosclerotic plaque (including those with atrial fibrillation), 40 (52.6%) had ≥50% ipsilateral stenosis. Conclusions The majority of symptomatic carotid artery FFT are likely caused by local plaque rupture, more than half of which are associated with moderate to severe carotid stenosis requiring revascularisation. However, a significant number of FFTs are caused by non-atherosclerotic mechanisms warranting additional investigations.
- 11 November 2022
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 8 (3) , 194-196
Open AccessAetiology of extracranial carotid free-floating thrombus in a prospective multicentre cohort
Background Carotid free-floating thrombi (FFT) in patients with acute transient ischaemic attack (TIA)/stroke have a high risk of early recurrent stroke. Management depends on aetiology, which can include local plaque rupture, dissection, coagulopathy, malignancy and cardioembolism. Our objectives were to classify the underlying aetiology of FFT and to estimate the proportion of patients with underlying stenosis requiring revascularisation. Methods We prospectively enrolled consecutive patients presenting to three comprehensive stroke centres with acute TIA/stroke and ipsilateral internal carotid artery FFT. The aetiology of FFT was classified as: carotid atherosclerotic disease, carotid dissection, cardioembolism, both carotid atherosclerosis and cardioembolism, or embolic stroke of uncertain source (ESUS). Patients with carotid atherosclerosis were further subclassified as having ≥50% or Results We enrolled 83 patients with confirmed FFT. Aetiological assessments revealed 66/83 (79.5%) had carotid atherosclerotic plaque, 4/83 (4.8%) had a carotid dissection, 10/83 (12%) had both atrial fibrillation and carotid atherosclerotic plaque and 3/83 (3.6%) were classified as ESUS. Of the 76 patients with atherosclerotic plaque (including those with atrial fibrillation), 40 (52.6%) had ≥50% ipsilateral stenosis. Conclusions The majority of symptomatic carotid artery FFT are likely caused by local plaque rupture, more than half of which are associated with moderate to severe carotid stenosis requiring revascularisation. However, a significant number of FFTs are caused by non-atherosclerotic mechanisms warranting additional investigations.
- 8 August 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 40, 113
Pre-Procedural Tricuspid Regurgitation in TMVr: Patient-Centric Outcomes
- 8 August 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 40, 113
Pre-Procedural Tricuspid Regurgitation in TMVr: Patient-Centric Outcomes
- 24 August 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (8) , E785-E793
Differentiating Carotid Free-Floating Thrombus From Atheromatous Plaque Using Intraluminal Filling Defect Length on CTA
Objective: To validate a previously proposed filling defect length threshold of >3.8 mm on CT-angiography (CTA) to discriminate between free-floating thrombus (FFT) and plaque of atheroma. Methods: Prospective multicenter observational study of 100 participants presenting with TIA/stroke symptoms and a carotid intraluminal filling defect on initial CTA. Follow-up CTA was obtained within one week, and at weeks 2 and 4 if the intraluminal filling defect was unchanged in length. Resolution or decreased length was diagnostic of FFT, whereas its static appearance after 4 weeks was indicative of plaque. Diagnostic accuracy of FFT length was assessed by receiver operating characteristic analysis. Results: Ninety-five participants (mean age [standard deviation], 68 [13] years; 61 men; 83 participants with FFT; 12 participants with a plaque) were evaluated. The >3.8 mm threshold had a sensitivity of 88% (73/83) (95% confidence interval {CI}: 78%, 94%) and specificity of 83% (10/12) (95% CI, 51%, 97%) (area under the curve [AUC], 0.91, p<.001) for the diagnosis of FFT. The optimal length threshold was >3.64 mm with a sensitivity of 89%( 74/83) (95% CI, 80%, 95%) and specificity of 83% (10/12) (95% CI, 51%, 97%). Adjusted logistic regression showed that every 1 mm increase in intraluminal filling defect length is associated with an increase in odds of FFT of 4.6 ([95% CI] 1.9-11.1; p=.01). Conclusion: CTA enables accurate differentiation of FFT versus plaque using craniocaudal length thresholds. Trial Registration Information: Clinical trial identifier:www.clinicaltrials.govNCT02405845 Classification of Evidence: This study provides Class I evidence that in patients with TIA/stroke symptoms, the presence of CTA-identified filling defects of length >3.8 mm accurately discriminates free-floating thrombus from atheromatous plaque.
- 24 August 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (8) , E785-E793
Differentiating Carotid Free-Floating Thrombus From Atheromatous Plaque Using Intraluminal Filling Defect Length on CTA
Objective: To validate a previously proposed filling defect length threshold of >3.8 mm on CT-angiography (CTA) to discriminate between free-floating thrombus (FFT) and plaque of atheroma. Methods: Prospective multicenter observational study of 100 participants presenting with TIA/stroke symptoms and a carotid intraluminal filling defect on initial CTA. Follow-up CTA was obtained within one week, and at weeks 2 and 4 if the intraluminal filling defect was unchanged in length. Resolution or decreased length was diagnostic of FFT, whereas its static appearance after 4 weeks was indicative of plaque. Diagnostic accuracy of FFT length was assessed by receiver operating characteristic analysis. Results: Ninety-five participants (mean age [standard deviation], 68 [13] years; 61 men; 83 participants with FFT; 12 participants with a plaque) were evaluated. The >3.8 mm threshold had a sensitivity of 88% (73/83) (95% confidence interval {CI}: 78%, 94%) and specificity of 83% (10/12) (95% CI, 51%, 97%) (area under the curve [AUC], 0.91, p<.001) for the diagnosis of FFT. The optimal length threshold was >3.64 mm with a sensitivity of 89%( 74/83) (95% CI, 80%, 95%) and specificity of 83% (10/12) (95% CI, 51%, 97%). Adjusted logistic regression showed that every 1 mm increase in intraluminal filling defect length is associated with an increase in odds of FFT of 4.6 ([95% CI] 1.9-11.1; p=.01). Conclusion: CTA enables accurate differentiation of FFT versus plaque using craniocaudal length thresholds. Trial Registration Information: Clinical trial identifier:www.clinicaltrials.govNCT02405845 Classification of Evidence: This study provides Class I evidence that in patients with TIA/stroke symptoms, the presence of CTA-identified filling defects of length >3.8 mm accurately discriminates free-floating thrombus from atheromatous plaque.
- 31 March 2017
- Published by Springer Nature in Neuroradiology
- Vol. 59 (5) , 471-475
Hypoattenuation on CTA images with large vessel occlusion: timing affects conspicuity
Parenchymal hypoattenuation distal to occlusions on CTA source images (CTASI) is perceived because of the differences in tissue contrast compared to normally perfused tissue. This difference in conspicuity can be measured objectively. We evaluated the effect of contrast timing on the conspicuity of ischemic areas.
- 31 March 2017
- Published by Springer Nature in Neuroradiology
- Vol. 59 (5) , 471-475
Hypoattenuation on CTA images with large vessel occlusion: timing affects conspicuity
Parenchymal hypoattenuation distal to occlusions on CTA source images (CTASI) is perceived because of the differences in tissue contrast compared to normally perfused tissue. This difference in conspicuity can be measured objectively. We evaluated the effect of contrast timing on the conspicuity of ischemic areas.